Tokyo, Oct. 2 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059212) titled 'Evaluation of efficiency and safety for lascufloxacin drip infusion use for atypical pneumonia,including mycoplasma ,and legionella in the Saitama western area' on Oct. 2.
Study Type:
Observational
Primary Sponsor:
Institute - saitama medical university
Condition:
Condition - atypical pneumonia,including mycoplasma ,and legionella
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Evaluation of efficiency and safety for lascufloxacin drip infusion use for atypical pneumonia,including mycoplasma ,and legionella in the Saitama western area.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
Gender - Male and Female
Key inclusion criteria - 1) the adult
2) the cases those were diagnosed as atypical pneumonia and will be LSFX will be administered
3) the case those will be accepted the switch therapy: intravenous to oral
Key exclusion criteria - 1) the cases those did not mycoplasma and legionella finally
2) the cases those have the contraindication for LSFX
3) the cases those have the too severe underlying diseases
Target Size - 50
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 10 Month 02 Day
Anticipated trial start date - 2025 Year 12 Month 01 Day
Last follow-up date - 2027 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067725
Disclaimer: Curated by HT Syndication.
